Skip to main content
Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.035
-0.045 (-4.17%)
Mar 9, 2026, 5:15 PM CET

STO:NEWBRY Income Statement

Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year
 TTM FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Nov '25 Aug '25 Aug '24 Aug '23 Aug '22 Aug '21
Revenue
36.7631.5736.8310.275.523.09
Revenue Growth (YoY)
14.21%-14.27%258.75%86.11%78.73%-
Cost of Revenue
24.3118.7420.86.323.952.58
Gross Profit
12.4512.8316.033.951.560.5
Selling, General & Admin
28.9827.7728.7720.8114.665.95
Other Operating Expenses
-0.35----0.12-0.01
Operating Expenses
34.4233.4430.522.0715.556.6
Operating Income
-21.97-20.61-14.47-18.12-13.99-6.1
Interest Expense
-1.66-1.65-1.53---0.04
Interest & Investment Income
0.020.020.20.16-0.11
Currency Exchange Gain (Loss)
-0.81-0.810.39-1.47-0.68-0.03
EBT Excluding Unusual Items
-24.95-23.06-15.41-19.43-14.67-6.06
Gain (Loss) on Sale of Assets
-0.55-0.55----
Pretax Income
-25.5-23.6-15.41-19.43-14.67-6.06
Income Tax Expense
0.280.28-0---
Net Income
-25.78-23.88-15.41-19.43-14.67-6.06
Net Income to Common
-25.78-23.88-15.41-19.43-14.67-6.06
Shares Outstanding (Basic)
2726212018-
Shares Outstanding (Diluted)
2726212018-
Shares Change (YoY)
21.53%21.08%9.68%9.68%--
EPS (Basic)
-0.94-0.92-0.72-1.00-0.82-
EPS (Diluted)
-0.94-0.92-0.72-1.00-0.82-
Gross Margin
33.87%40.63%43.53%38.46%28.35%16.26%
Operating Margin
-59.78%-65.27%-39.29%-176.51%-253.57%-197.67%
Profit Margin
-70.13%-75.65%-41.83%-189.28%-265.90%-196.43%
EBITDA
-20.84-19.6-13.65-17.78-13.89-
EBITDA Margin
-56.70%-62.08%-37.05%-173.17%-251.87%-
D&A For EBITDA
1.131.010.820.340.09-
EBIT
-21.97-20.61-14.47-18.12-13.99-6.1
EBIT Margin
-59.78%-65.27%-39.29%-176.51%-253.57%-197.67%
Revenue as Reported
34.2134.2139.7411.177.243.1
Source: S&P Capital IQ. Standard template. Financial Sources.